Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab first-line treatment in extensive-stage small-cell lung cancer: real-world safety study
ChiCTR2300074932Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adebrelimab in small cell lung cancer (SCLC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Safety. Started Aug 2023; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300074932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074932.